Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases, Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs), & Region - Global Forecast to 2028
Report Code: PH 3772 Oct, 2023, by marketsandmarkets.com
The clinical trial supplies market is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9 % during the forecast period. Integration of big data analytics, AI and blockchain technology in clinical trial supplies with an aim to enhances data integrity, traceability and security, optimize supply chains is likely to propel the growth of clinical trial supplies market. Furthermore, the shift of patients towards personalized medicines have led to the development & demand of customized clinical trial supplies which further likely to boost the growth of the market. Additionally, rise in outsourcing of clinical trials is also contributing to the market growth.
Attractive Opportunities in the Clinical Trial Supplies Market
To know about the assumptions considered for the study, Request for Free Sample Report
Global Clinical Trial Supplies Market Dynamics
Drivers: Increasing the number of registered clinical trials
According to the World Health Organization (WHO) there has been an increase, in the number of trials registered in 2022 compared to the previous year. Globally 56,793 clinical trials were registered. The United States had the number of trials registered from 1999 to 2022 (168,520) followed by China (94,193) and Japan (63,499). Among the identified phases of development phase II trials accounted for the share at 95,790.
The rise in trials across medical fields such as oncology, neurology and rare diseases is driving up the demand for clinical trial supplies, like logistics, packaging, labeling, storage and distribution. This surge is contributing to market growth
Restraints: High cost of drug development
The significant expense of developing drugs poses an obstacle to the expansion of the clinical trial supplies industry. Pharmaceutical and biotech firms encounter rising costs linked to R&D conducting trials adhering to regulations and managing the supply chain. These expenses involve acquiring trial materials handling logistics and ensuring storage to uphold quality and compliance during the trial phase. Due to these factors, small and mid-sized businesses are likely to invest less in expandable clinical studies, so restricting the need for clinical trial materials.
Opportunities: Growth opportunities in emerging markets
Emerging markets are driving significant increase in the clinical trial supply business. Rising healthcare infrastructure, higher R&D spending, and favourable regulatory environments and growing popularity among these areas for clinical trials define these regions. This tendency is influenced by big patient populations, varied demographics, and cheaper running costs than in developed nations. These advantages are used by pharmaceutical and biotechnological firms to run low-cost studies and cut the length of medication development. Consequently, suppliers of clinical trials are becoming more visible in these fields, thereby boosting global clinical research innovation and driving general market expansion.
Moreover, the expansion of major industry players in the market is probably going to result in profitable development for the clinical trial supplies market. For example, Catelent Inc. (US) acquired Bomi Group to help the expansion in healthcare logistics by raising cold chain capacity in important European and Latin American markets and thus strengthening the company's worldwide presence.
Challenges: The high cost of clinical trials is a major hindrance to the clinical trial supplies market growth
One of the main difficulties of the expansion of the clinical trial supply market is their enormous cost. The growing demand to gather enough clinical data is one of the elements driving up the expenses of clinical studies. Furthermore, offering the comprehensive information about the forthcoming trends and issues that will have a significant impact on the market development in future is this clinical trial supplies market study report. In clinical trial research and development (R&D) expenses were somewhat expensive.
The pharmaceutical and biotechnology companies segment accounted for the largest share in 2022
Based on end users, the clinical trial supplies market is further segmented into, pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. Rising numbers of clinical trials for chronic illnesses conditions and higher expenditure in medication discovery and development help the pharmaceutical and biotechnology firms to hold the largest share in 2022. Moreover, development in the outsourcing tendency to lower expenses, speed up trial schedules, and provide specialised knowledge is probably going to help the expansion CRO sector.
North America was the largest regional market for Clinical trial supplies market in 2022.
The market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the market in 2022; this trend is projected to last throughout the forecast period. Key pharmaceutical and biotechnology businesses supported by a reputable network of Contract Research Organisations (CROs) and clinical trial supply providers are helping North America to be dominant in the clinical trial supplies market.
Over the course of the forecast, Asia Pacific is expected to expand somewhat quickly. One of the elements responsible for the expansion is the increase in clinical trials conducted by biotechnology and pharmaceutical businesses. Moreover, the availability of a sizable and varied patient population, less running costs than in industrialised countries, and strong legislative backing for clinical research is probably going to drive regional market expansion.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
Key players in the market include Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US), Nuvisan (Germany), Lonza Group (Switzerland), OCT Group LLC (US), Corex Logistic Limited (Ireland), Acnos Pharma GMBH (Germany), Clinical Service International (UK), Klifo (Denmark), Clinigen Limited (UK), Ancillare LP (US), N-Side (Europe), ADAllen pharma (UK), Durbin (UK), Recipharm AB (Sweden), IPS Pharma (UK).
Scope of the Clinical Trial Supplies Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$3.9 billion |
|
Estimated Value by 2028 |
$6.3 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 9.9% |
|
Market Driver |
Increasing the number of registered clinical trials |
|
Market Opportunity |
Growth opportunities in emerging markets |
This report categorizes the clinical trial supplies market to forecast revenue and analyze trends in each of the following submarkets:
By Service
- Logistics & Distribution
- Storage & Retention
- Packaging, Labelling & Blinding
- Manufacturing
- Comparator Sourcing
- Other Services (Solutions and Ancillary supplies)
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
- BA/BE Studies
By Type
- Small-Molecules
- Biologic Drugs
- Medical Devices
By Therapeutic Area
- Oncology
- Infectious Diseases
- Neurology
- Metabolic Disorders
- Immunology
- Cardiology
- Genetic Diseases
- Other Therapeutic Areas (Respiratory diseases, dermatological conditions, rare diseases, ENT diseases, and nephrology)
By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organisations (CRO's)
- Medical Device Companies
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Netherlands
- Rest of Europe (ROE)
-
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Rest of Asia Pacific
-
Latin America
- Mexico
- Brazil
- RoLATAM
- Middle East
- Africa
Recent Developments Clinical Trial Supplies Industry
- In July 2023, Thermo Fisher Scientific Inc. (US) and national minority quality forum (NMQF) entered into collaboration with the), which is a non-profit organization dedicated to research and education. This collaboration facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC) in order to increase the inclusion of historically underprivileged patient groups in clinical research.
- In April 2023, Almac Group (UK), introduced the IXRS3 Partnership Network, designed to expedite the creation and deployment of advanced eClinical solutions for biopharmaceutical sponsors.
- In March 2023, Icon Plc (Ireland) and LEO Pharma (Denmark) entered into a strategic partnership in order to enhance LEO Pharma's clinical trial operations, focusing on patient-centricity, cost-efficiency and to strengthen LEO Pharma.
- In August 2022, Marken (US) acquired Bomi Group (Italy) to boost cold chain capacity in key European and Latin American countries and therefore help the expansion in healthcare logistics by strengthening the company's worldwide presence.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global clinical trial supplies market?
The global clinical trial supplies market boasts a total revenue value of $6.3 billion by 2028.
What is the estimated growth rate (CAGR) of the global clinical trial supplies market?
The global clinical trial supplies market has an estimated compound annual growth rate (CAGR) of 9.9% and a revenue size in the region of $3.9 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2022)
4.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2023 VS. 2028
4.4 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2022
4.5 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.3 CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS
5.3.1 DRIVERS
5.3.1.1 Increasing R&D investments by biopharma companies
5.3.1.2 Growing number of clinical trials
5.3.1.3 Growing decentralization of clinical trials
5.3.1.4 Rising prevalence of orphan and rare diseases
5.3.1.5 Increasing outsourcing activities in emerging Asian economies
5.3.2 RESTRAINTS
5.3.2.1 High cost of drug development
5.3.3 OPPORTUNITIES
5.3.3.1 Growth opportunities in emerging markets
5.3.3.2 Increased investments in development of biologics and biosimilars
5.3.3.3 Rising demand for specialized testing services
5.3.4 CHALLENGES
5.3.4.1 High cost of clinical trials
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICING ANALYSIS OF OVERALL CLINICAL TRIALS, BY PHASE.
5.6 TECHNOLOGY ANALYSIS
5.6.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT)
5.7 VALUE CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 KEY CONFERENCES & EVENTS IN 2023–2024
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY LANDSCAPE FOR CLINICAL TRIAL SUPPLIES
5.11.1.1 North America
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.1.4 Rest of the World
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR CLINICAL TRIAL SUPPLY SERVICES
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE (Page No. - 81)
6.1 INTRODUCTION
6.2 LOGISTICS & DISTRIBUTION
6.2.1 INCREASING COMPLEXITY AND EVOLVING TREATMENT PROTOCOLS TO DRIVE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES
6.3 STORAGE & RETENTION
6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH
6.4 PACKAGING, LABELING, AND BLINDING
6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE SEGMENTAL GROWTH
6.5 MANUFACTURING
6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH
6.6 COMPARATOR SOURCING
6.6.1 INTENSE MARKET COMPETITION AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH
6.7 OTHER SERVICES
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE (Page No. - 101)
7.1 INTRODUCTION
7.2 PHASE III
7.2.1 LARGE PATIENT POPULATION ASSOCIATED WITH PHASE III TRIALS TO DRIVE DEMAND
7.3 PHASE II
7.3.1 ABILITY OF PHASE II CLINICAL TRIALS TO PROVIDE CLARITY ON EFFECTIVENESS AND SAFETY OF DRUGS TO DRIVE MARKET GROWTH
7.4 PHASE I
7.4.1 IMPORTANCE OF QUALITY CLINICAL TRIAL SUPPLIES IN PHASE I CLINICAL TRIALS TO BOOST MARKET
7.5 PHASE IV
7.5.1 INCREASING NUMBER OF STUDIES UNDER PHASE IV TRIAL TO SUPPORT GROWTH
7.6 BA/BE STUDIES
7.6.1 INCREASING PATENT EXPIRATION TO INCREASE DEMAND FOR BA/BE STUDIES
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE (Page No. - 117)
8.1 INTRODUCTION
8.2 SMALL-MOLECULE DRUGS
8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH
8.3 BIOLOGIC DRUGS
8.3.1 RELATIVELY LOW RATE OF ATTRITION OF BIOLOGIC DRUGS COMPARED TO SMALL-MOLECULE DRUGS TO BOOST GROWTH
8.4 MEDICAL DEVICES
8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO SUPPORT GROWTH
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA (Page No. - 128)
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH
9.3 INFECTIOUS DISEASES
9.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ACCELERATE EFFORTS TO DEVELOP NEW DRUGS
9.4 NEUROLOGY
9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR NEUROLOGY RESEARCH TO DRIVE GROWTH
9.5 METABOLIC DISORDERS
9.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH
9.6 IMMUNOLOGY
9.6.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL DEMAND FOR CLINICAL TRIAL SUPPLIES
9.7 CARDIOLOGY
9.7.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH
9.8 GENETIC & RARE DISEASES
9.8.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE DEMAND
9.9 OTHER THERAPEUTIC AREAS
10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER (Page No. - 160)
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 INCREASING OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMA & BIOTECH COMPANIES TO BOOST MARKET
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
10.4 MEDICAL DEVICE COMPANIES
10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET
11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION (Page No. - 170)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Increasing R&D investments to drive market growth in US
11.2.2 CANADA
11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies in Germany
11.3.2 UK
11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth
11.3.3 FRANCE
11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France
11.3.4 ITALY
11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies in Italy
11.3.5 SPAIN
11.3.5.1 Increasing biologics production to support market growth in Spain
11.3.6 SWITZERLAND
11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market in Switzerland
11.3.7 NETHERLANDS
11.3.7.1 Increasing pharmaceutical production to boost clinical trial supplies market in Netherlands
11.3.8 REST OF EUROPE
11.3.9 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.1.1 Favorable government regulations to boost market growth in China
11.4.2 JAPAN
11.4.2.1 Government initiatives for drug innovation to support market growth
11.4.3 INDIA
11.4.3.1 Low manufacturing costs and skilled workforce to attract outsourcing and investments to India
11.4.4 AUSTRALIA
11.4.4.1 Presence of many research institutes conducting clinical trials to boost market growth
11.4.5 SOUTH KOREA
11.4.5.1 Government investments to contribute to market growth in South Korea
11.4.6 SINGAPORE
11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore
11.4.7 REST OF ASIA PACIFIC
11.4.8 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.1.1 Growth in pharmaceutical R&D to support market growth
11.5.2 MEXICO
11.5.2.1 Growing number of Phase III clinical trials to drive market growth
11.5.3 REST OF LATIN AMERICA
11.5.4 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST
11.6.1 GROWING PRESENCE OF PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
11.6.2 MIDDLE EAST: RECESSION IMPACT
11.7 AFRICA
11.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 255)
12.1 INTRODUCTION
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY FOOTPRINT
12.6.1 SERVICE FOOTPRINT OF TOP 25 COMPANIES
12.6.2 REGIONAL FOOTPRINT OF TOP 25 COMPANIES
12.7 COMPANY EVALUATION MATRIX: START-UPS/SMES
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
12.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
12.9 COMPETITIVE SCENARIO AND TRENDS
12.9.1 SERVICES LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 OTHER DEVELOPMENTS
13 COMPANY PROFILES (Page No. - 270)
13.1 KEY MARKET PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC, INC.
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 CATALENT, INC.
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 EUROFINS SCIENTIFIC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 MnM view
13.1.3.3.1 Key strengths
13.1.3.3.2 Strategic choices
13.1.3.3.3 Weaknesses & competitive threats
13.1.4 PIRAMAL PHARMA SOLUTIONS
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.3 Recent developments
13.1.5 PRA HEALTH SCIENCES (A SUBSIDIARY OF ICON PLC)
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.6 MARKEN (A SUBSIDIARY OF UPS)
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.7 PAREXEL INTERNATIONAL (MA) CORPORATION
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.8 BIOCAIR
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.8.3 Recent developments
13.1.9 ALMAC GROUP
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.10 SHARP SERVICES, LLC
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.11 PCI PHARMA SERVICES
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.12 NUVISAN
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.13 LONZA GROUP
13.1.13.1 Business overview
13.1.13.2 Services offered
13.2 OTHER PLAYERS
13.2.1 OCT GROUP LLC
13.2.2 COREX LOGISTICS LIMITED
13.2.3 ACNOS PHARMA GMBH
13.2.4 CLINICAL SERVICES INTERNATIONAL
13.2.5 KLIFO
13.2.6 CLINIGEN LIMITED
13.2.7 ANCILLARE LP
13.2.8 N-SIDE
13.2.9 ADALLEN PHARMA
13.2.10 DURBIN
13.2.11 RECIPHARM AB
13.2.12 IPS PHARMA
14 APPENDIX (Page No. - 320)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
LIST OF TABLES (306 TABLES)
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
TABLE 4 R&D INVESTMENTS BY MAJOR PLAYERS (2022)
TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022
TABLE 6 PHASE III ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES)
TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN)
TABLE 8 CLINICAL TRIAL SUPPLIES MARKET: SUPPLY CHAIN ANALYSIS
TABLE 9 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 16 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 17 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LABELING, AND BLINDING SERVICES, COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 48 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 90 NEW FDA-APPROVED ONCOLOGY DRUGS (2023)
TABLE 91 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 97 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 102 CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 103 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 108 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
TABLE 113 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023)
TABLE 119 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 120 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 125 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 126 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 129 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
TABLE 130 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 131 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 134 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 136 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 137 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 138 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 139 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 142 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 143 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 145 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 147 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 148 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 150 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 151 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 152 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 154 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 155 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 157 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 158 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 159 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 160 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 162 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 163 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 164 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 165 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 167 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 168 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 169 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 170 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 171 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 173 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 174 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 175 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 176 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 178 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 179 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 180 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 181 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 183 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 184 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 185 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 186 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 188 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 189 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 190 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 191 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 193 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 194 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 195 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 196 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 198 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 199 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 200 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 201 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 203 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 204 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 205 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 206 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 208 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 209 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 210 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 211 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 212 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 213 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 214 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 216 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 217 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 220 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 221 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 222 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 224 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 225 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 226 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 227 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 228 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 229 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 230 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 231 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 232 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 233 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 234 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 235 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 236 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 237 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 239 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 240 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 241 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 242 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 243 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 244 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 245 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 246 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 247 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 248 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 249 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 255 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 256 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 257 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 258 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 259 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 260 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 261 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 262 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 263 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 264 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 265 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 266 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 267 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 268 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 269 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 270 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 276 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 277 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 278 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 281 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
TABLE 282 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)
TABLE 283 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 284 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 285 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 286 CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION
TABLE 287 CLINICAL TRIAL SUPPLIES MARKET: COMPANY SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 288 CLINICAL TRIAL SUPPLIES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 289 CLINICAL TIAL SUPPLIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 290 CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
TABLE 291 CLINICAL TRIAL SUPPLIES MARKET: SERVICE LAUNCHES, JANUARY 2021–AUGUST 2023
TABLE 292 CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–JULY 2023
TABLE 293 CLINICAL TRIAL SUPPLIES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2023
TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 295 CATALENT, INC.: BUSINESS OVERVIEW
TABLE 296 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
TABLE 297 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
TABLE 298 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
TABLE 299 UPS: BUSINESS OVERVIEW
TABLE 300 PAREXEL INTERNATIONAL (MA) CORPORATION: BUSINESS OVERVIEW
TABLE 301 BIOCAIR: BUSINESS OVERVIEW
TABLE 302 ALMAC GROUP: BUSINESS OVERVIEW
TABLE 303 SHARP SERVICES, LLC: BUSINESS OVERVIEW
TABLE 304 PCI PHARMA SERVICES: BUSINESS OVERVIEW
TABLE 305 NUVISAN: BUSINESS OVERVIEW
TABLE 306 LONZA GROUP: BUSINESS OVERVIEW
LIST OF FIGURES (49 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET: PRIMARY RESPONDENTS
FIGURE 3 CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 7 CLINICAL TRIAL SUPPLIES MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
FIGURE 8 CLINICAL TRIAL SUPPLIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET
FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIAL SUPPLIES MARKET IN 2022
FIGURE 18 LOGISTICS & DISTRIBUTION SERVICES TO CONTINUE TO DOMINATE MARKET IN 2028
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028
FIGURE 21 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 NUMBER OF REGISTERED CLINICAL TRIALS (2011–2022)
FIGURE 23 ONGOING CLINICAL TRIALS, BY PHASE (% SHARE), 2022
FIGURE 24 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023)
FIGURE 25 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHED WITH ORPHAN DRUG DESIGNATION, 2012–2022
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022)
FIGURE 27 BIOSIMILAR APPROVALS AND LAUNCHES (2015–2022)
FIGURE 28 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
FIGURE 29 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SUPPLY SERVICES
FIGURE 31 KEY BUYING CRITERIA FOR END USERS
FIGURE 32 US CANCER INCIDENCE IN MALES, BY TYPE (2022)
FIGURE 33 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022)
FIGURE 34 GLOBAL ONCOLOGY-RELATED CLINICAL TRIALS, 2010–2021 (THOUSAND)
FIGURE 35 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
FIGURE 36 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
FIGURE 38 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
FIGURE 41 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
FIGURE 42 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
FIGURE 44 CATALENT, INC.: COMPANY SNAPSHOT (2022)
FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
FIGURE 46 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
FIGURE 47 ICON PLC: COMPANY SNAPSHOT (2022)
FIGURE 48 UPS: COMPANY SNAPSHOT (2022)
FIGURE 49 LONZA GROUP: COMPANY SNAPSHOT (2022)
This study involved four major activities in estimating the current size of the clinical trial supplies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the clinical trial supplies market. The secondary sources used for this study include Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Food and Drug Administration (FDA), Committee for Medicinal Products for Human Use (CHMP), ClinicalTrials.gov, Association of Clinical Research Professionals (ACRP), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), World Health Organization (WHO), Indian Society for Clinical Research (ISCR), Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the clinical trial supplies market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the clinical trial supply service business of players operating in the market have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Market Size Estimation Methodology-Bottom-up approach
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach-
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The clinical trial supplies market includes the supply services which are required throughout the process of new drug development. And these services are provided either as end-to-end services throughout the drug development process or as a part of the supply chain of clinical trial supplies.
Key Stakeholders
- Pharmaceutical and biopharmaceutical companies
- Companies Developing Medical Devices
- Manufacturers of clinical trial supplies
- Contract manufacturing organizations (CMOs)
- Life science research institutes
- Venture Capitalists
- Research and consulting firms
Report Objectives
- To define, describe, and forecast the clinical trial supplies market by service, type, phase, therapeutic area, end user and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall clinical trial supplies market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and the Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product launches, acquisitions partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Service Analysis
- Service matrix, which provides a detailed comparison of the service portfolio of each company in the Clinical Trial Supplies Market
Generating Response ...
Growth opportunities and latent adjacency in Clinical Trial Supplies Market
What are the major growth strategies prevalent in the Clinical Trial Supplies Market?
Which factors are influencing the global growth of Clinical Trial Supplies Market?
Which are the different geographies covered in the global study of Clinical Trial Supplies Market?